TORONTO, March 20, 2018 -- Route1 Inc. (OTCQB:ROIUF) (TSX-V:ROI) (the “Company” or “Route1”), a leader in secure data protection technologies and user authentication for government and enterprise, today announced that the Patent and Trial Appeal Board (“PTAB”) of the US Patent and Trademark Office earlier today denied the institution of the inter partes review (“IPR”) sought by AirWatch LLC (“AirWatch”).
Route1 filed a complaint against AirWatch in federal court in Delaware on March 27, 2017, alleging that AirWatch is infringing Route1’s U.S. Patent No 7,814,216 (the “’216 Patent”). The civil action number is 1:17-cv-00331-RGA and was assigned to the Honorable Richard G. Andrews. On September 22, 2017, AirWatch filed an IPR petition with the PTAB seeking a determination that the claims of the ‘216 Patent are invalid. Route1 filed its preliminary response to the IPR petition on December 22, 2017. The PTAB issued its decision determining that AirWatch had not demonstrated a reasonable likelihood that it would prevail in establishing that any claims of the ‘216 patent are invalid and, accordingly, denied the IPR petition. AirWatch has 30 days to file a motion for reconsideration.
About Route1 Inc.
Route1 Inc. is a world-leader in secure data protection technologies and user authentication for government and enterprise. Route1 solutions enable the workforce to be more productive and more flexible without compromising system access, data-at-rest, or data-in-use. The Company’s suite of patented enterprise security solutions combines best-in-class authentication, data security and secure communications with streamlined administration tools, running on a proven, trusted infrastructure. From mobile access to business continuity to best-in-class full system encryption, Route1 offers the most effective, affordable methods to secure the digital fortress, while meeting or exceeding the highest standards for government and industry. Route1 has Full Authority to Operate from the U.S. Department of Defense, the U.S. Department of the Navy, the U.S. Department of the Interior, and other government agencies. The Company is also trusted by enterprise security teams in the banking, healthcare, legal and education sectors, among others. With offices in Washington, D.C., Boca Raton, FL and Toronto, Canada, Route1 serves public and private sector clients around the world. Route1 is listed on the OTCQB in the United States under the symbol ROIUF and in Canada on the TSX Venture Exchange under the symbol ROI. For more information, visit: www.route1.com.
For More Information Contact:
Route1 Inc.
Peter Chodos
EVP and CFO, Route1 Inc.
+1 416 814-2619
[email protected]
This news release, required by applicable Canadian laws, does not constitute an offer to sell or a solicitation of an offer to buy any of the securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
© 2018 Route1 Inc. All rights reserved. No part of this document may be reproduced, transmitted or otherwise used in whole or in part or by any means without prior written consent of Route1 Inc. See https://www.route1.com/terms-of-use/ for notice of Route1’s intellectual property.


Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
Infineon Raises 2026 Revenue Outlook as AI Data Center Demand Fuels Record Quarterly Sales
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing
DHL Q2 Profit Jumps 24% as Express Business Drives Growth
Shein Targets $30B-$40B Valuation in Hong Kong IPO Planned for August
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
DeepSeek to Raise AI API Prices as Demand for New Models Surges
Meta AI Model Exploits Security Flaw During Cybersecurity Test, Raising AI Safety Concerns
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 



